argenx SE (NASDAQ:ARGX - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $664.20 and last traded at $662.59, with a volume of 269970 shares. The stock had previously closed at $656.26.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on ARGX. Piper Sandler increased their price target on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. HC Wainwright restated a "buy" rating and set a $617.00 price target on shares of argenx in a research note on Wednesday, November 20th. Evercore ISI upped their price objective on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st. JPMorgan Chase & Co. raised their target price on argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Finally, William Blair raised argenx from a "market perform" rating to an "outperform" rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $645.61.
Get Our Latest Research Report on ARGX
argenx Price Performance
The company has a fifty day moving average price of $613.51 and a 200 day moving average price of $549.46. The company has a market cap of $40.47 billion, a PE ratio of -761.82 and a beta of 0.59.
argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same quarter last year, the company posted ($1.25) EPS. As a group, sell-side analysts predict that argenx SE will post 2.2 EPS for the current fiscal year.
Institutional Investors Weigh In On argenx
Several institutional investors have recently bought and sold shares of the stock. Cromwell Holdings LLC lifted its holdings in argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC grew its stake in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after purchasing an additional 56 shares during the period. Point72 Hong Kong Ltd bought a new position in argenx in the second quarter worth $76,000. Fulton Bank N.A. purchased a new position in argenx during the fourth quarter valued at $226,000. Finally, Blue Trust Inc. boosted its holdings in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock valued at $201,000 after buying an additional 298 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.
About argenx
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
